NHS Innovation Accelerator
Mark Lomax is a seasoned healthcare executive with extensive experience in leading innovative healthcare initiatives and organizations. Currently serving as the Chief Executive Officer at PEP Health, Mark focuses on analyzing patient feedback from social media and improving hospital services in the USA and UK. As a NHS Innovation Accelerator Fellow, Mark is dedicated to scaling PEP Health within the NHS. Previously, Mark held the position of Non-Executive Chairman at Emma Virtual Ltd, providing strategic direction and funding for a virtual assistant start-up. Mark’s track record includes interim roles supporting high growth for PE/VC backed businesses, as well as significant leadership positions such as General Manager at GenesisCare UK, where Mark successfully led the establishment of new cancer centers. Mark founded and grew MediHome, offering solutions to global healthcare challenges before its successful sale. Mark holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from St Bartholomew's Medical School.
This person is not in the org chart
This person is not in any teams
NHS Innovation Accelerator
1 followers
The NHS Innovation Accelerator (NIA) is an NHS England Initiative delivered in partnership with the country’s 15 Health Innovation Networks (HINs) and the Accelerated Access Collaborative. Hosted by UCLPartners, it supports delivery of the Five Year Forward View by accelerating uptake of high impact innovations for patient, population and NHS staff benefit, and providing real time practical insights on spread to inform national strategy. Fellows supported by the NIA all share a set of values and passion for scaling evidence-based innovation to benefit a wider population, with a commitment to share their learnings. Some impressive results have been achieved by Fellows since the NIA launched in July 2015: 2,980 additional NHS sites now using NIA innovations; £203 million in external funds secured; 193 awards won; 1,145 jobs created; and 57 innovations selling internationally. In addition, impact data is already available at adopter sites and this demonstrates earlier intervention, reductions in complications and emergency admissions, alongside cost savings.